Comparing of Verastem Inc. (VSTM) and Clovis Oncology Inc. (NASDAQ:CLVS)

Verastem Inc. (NASDAQ:VSTM) and Clovis Oncology Inc. (NASDAQ:CLVS) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verastem Inc. 2 4.44 N/A -1.26 0.00
Clovis Oncology Inc. 19 2.38 N/A -7.16 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Verastem Inc. 0.00% -80% -40.8%
Clovis Oncology Inc. 0.00% -196.4% -43%

Risk & Volatility

A 2.91 beta means Verastem Inc.’s volatility is 191.00% more than Standard and Poor’s 500’s volatility. Clovis Oncology Inc.’s 81.00% more volatile than Standard and Poor’s 500 volatility due to the company’s 1.81 beta.

Liquidity

Verastem Inc.’s Current Ratio is 7.6 while its Quick Ratio is 7.6. On the competitive side is, Clovis Oncology Inc. which has a 4.4 Current Ratio and a 4.2 Quick Ratio. Verastem Inc. is better positioned to pay off short and long-term obligations compared to Clovis Oncology Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Verastem Inc. and Clovis Oncology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Verastem Inc. 0 0 4 3.00
Clovis Oncology Inc. 0 3 3 2.50

Verastem Inc. has a 578.29% upside potential and a consensus target price of $8.75. Competitively Clovis Oncology Inc. has a consensus target price of $25.86, with potential upside of 397.31%. The information presented earlier suggests that Verastem Inc. looks more robust than Clovis Oncology Inc. as far as analyst view.

Institutional & Insider Ownership

Roughly 47% of Verastem Inc. shares are owned by institutional investors while 0% of Clovis Oncology Inc. are owned by institutional investors. Insiders owned roughly 0.4% of Verastem Inc.’s shares. Competitively, insiders own roughly 0.5% of Clovis Oncology Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Verastem Inc. 13.64% 6.38% -28.23% -53.42% -80.05% -55.36%
Clovis Oncology Inc. -4.7% -31.27% -40.43% -57.11% -75.79% -41.26%

For the past year Verastem Inc.’s stock price has bigger decline than Clovis Oncology Inc.

Summary

Verastem Inc. beats Clovis Oncology Inc. on 7 of the 9 factors.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The companyÂ’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The companyÂ’s duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier; and a clinical collaboration with Bristol-Myers Squibb Company to evaluate combination of Opdivo (Nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.